Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Recruiting · Phase 2 · NCT06787612
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
At a glance
- Research payments reported, 2025
- $647,337
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 397
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Ubamatamab (drug), Bevacizumab (drug), Cemiplimab (drug), Fianlimab (drug), PLD (drug), Sarilumab (drug), REGN10597 (drug)
- Dates
- Started 2025-05-28; completion 2028-06-30
- Results posted
- Not yet
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug is in the blood at different times * Whet…
From ClinicalTrials.gov, last updated 2026-11-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $647,337 in research payments for this study in 2025 (148 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rebecca Arend, M.D. Gynecologic Oncology · Birmingham, AL
- Navid Hafez, M.D. Hematology & Oncology · Los Angeles, CA
- Matthew L. Anderson, MD OB-GYN (Obstetrics & Gynecology) · Tampa, FL
- Gerardo Colon-otero, MD Hematology & Oncology · Jacksonville, FL
- John Moroney Gynecologic Oncology · Chicago, IL
- Ira S. Winer, MD Gynecologic Oncology · Royal Oak, MI
- David C. Starks, MD Gynecologic Oncology · Sioux Falls, SD
- Fernanda Musa, M.D. Gynecologic Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Avera Mckennan Hospital & University Health Center, SD $181,011
- Swedish Medical Center, WA $161,312
- University of Alabama Hospital, AL $60,216
- University of South Florida $57,583
- Cedars-Sinai Medical Center, CA $51,317
- Karmanos Cancer Center, MI $43,540
- Mayo Clinic Jacksonville $41,460
- The University of Chicago $32,754
- $18,144
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.